MGTX
MeiraGTx Holdings plc
NASDAQ · USHealthcareBiotechnology
$12.21-1.85%
Price as of Jul 20, 2026
MGTX financials
MeiraGTx Holdings plc financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $81.4M | $33.3M | $14.0M | $15.9M |
| Cost of revenue | $4.8M | $23.8M | $0.00 | $0.00 |
| Gross profit | $76.5M | $9.5M | $14.0M | $15.9M |
| Operating expenses | $182.5M | $173.7M | $151.1M | $132.3M |
| Operating income | -$106.0M | -$164.2M | -$137.1M | -$116.4M |
| Net income | -$114.2M | -$147.8M | -$84.0M | -$129.6M |
| EBITDA | -$89.4M | -$121.7M | -$57.1M | -$116.1M |
| Basic EPS | $-1.42 | $-2.12 | $-1.49 | $-2.87 |
| Diluted EPS | $-1.42 | $-2.12 | $-1.49 | $-2.87 |
| Balance sheet | ||||
| Cash & equivalents | $65.9M | $103.7M | $129.6M | $115.5M |
| Total assets | $244.4M | $269.8M | $326.7M | $318.2M |
| Total liabilities | $250.2M | $201.9M | $188.6M | $200.5M |
| Stockholders’ equity | -$5.8M | $67.8M | $138.2M | $117.7M |
| Total debt | $88.7M | $84.8M | $89.3M | $92.2M |
| Net debt | $22.8M | -$18.9M | -$40.3M | -$23.3M |
| Cash flow | ||||
| Operating cash flow | -$46.4M | -$104.5M | -$105.4M | -$73.1M |
| Capital expenditure | -$3.8M | -$5.0M | -$20.2M | -$45.0M |
| Free cash flow | -$50.2M | -$109.5M | -$125.5M | -$118.1M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |